Trastuzumab PHERGain Trial: Unveiling 3-Year iDFS in HER2+ Early Breast Cancer Breast 2 Mins Read2 Dr. Javier Cortes discussed the PHERGain clinical study is a phase 2 trial focused on the potential deescalation of chemotherapy…
Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial Lisa Kachnic MD Gastrointestinal 13 Mins Read1 Trimodality: In addition to Trastuzumab for HER2+ Esophageal Adenocarcinoma: NRG Oncology RTOG 1010 Phase III Trial Lisa Kachnic MD By…
T-DXd Interstitial Lung Disease: Controllable Adverse Event? Lung 12 Mins Read0 Is Interstitial Lung Disease a Manageable Adverse Event of Trastuzumab T-DXd Deruxtecan Treatment? What is Trastuzumab T-DXd? Trastuzumab T-DXd is…
